한글목차

2024년에는 16개국에서 226,000명 이상의 다계통위축증(MSA) 환자가 발생할 것으로 예상되고 있습니다.

현재 MSA 치료제로 승인된 것은 단 하나뿐이며, MSA 파이프라인은 41개의 분자를 보유하고 있으며, 등록 전 단계나 3상 개발 단계에 있는 것은 하나도 없습니다. 10개의 분자가 임상 2상 개발 단계에 있습니다.

지난 10년간 MSA를 대상으로 60건의 임상시험이 진행되었습니다. 2019년과 2023년에 가장 많은 임상시험이 시작됐습니다(각 8건). 지난 10년간 북미와 유럽에서 가장 많은 라이선스 계약이 체결됐습니다.

이 보고서는 세계의 다계통위축증(MSA) 시장을 조사했으며, 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 병 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 시판약
• 작용기전별 개요
• 분자 유형별 개요
• 제품 개요와 판매 예측

제5장 가격 결정과 상환 평가

제6장 파이프라인 의약품 평가

제7장 임상시험 평가

• 역사적 개요
• 상별 개요
• 현황별 개요
• 진행중 및 계획중인 시험 상별 개요
• 가상 컴포넌트 시험
• 지역 시험 개요
• 지역별 단일국 및 다국간 시험
• 상별 스폰서 상위 20개사
• 현황별 스폰서 상위 20개사
• 엔드포인트 현황별 개요
• 인종 및 민족별 개요
• 등록 데이터
• 임상시험 시행 시설 주요 20개국
• 세계의 주요 20개 시설
• 실현 가능성 분석 - 지역 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

• 주요 시장 진출기업

제10장 향후 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Multiple System Atrophy therapeutics.

In 2024, more than 226,000 diagnosed prevalent cases of MSA are anticipated in the 16 countries covered in GlobalData's epidemiology forecast.

Currently, there is only one approved therapy available on the market for MSA.

The MSA pipeline holds 41 molecules, with no assets in the pre-registration stage or Phase III development. There are 10 assets in Phase II development.

Over the past 10 years, 60 clinical trials have been conducted in MSA. The highest number of studies were initiated in 2019 and 2023 (eight trials each).

During the past decade, licensing agreements were the most frequent type of deal in North America and Europe.

Scope

GlobalData's Multiple System Atrophy: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Multiple System Atrophy market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Multiple System Atrophy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer